Immutep’s First-in-Human Autoimmune Drug Clears Safety Bar With Phase I Win

By Josua Ferreira -

Immutep hits pivotal Phase I milestone as IMP761 data turns heads at EULAR 2026

Immutep Limited (ASX: IMM) presented first-in-human clinical data for IMP761 at the European Alliance of Associations for Rheumatology (EULAR) Congress in London on 4 June 2026, marking a significant public debut for the company’s lead autoimmune candidate. The Phase I study met its primary endpoint in the single ascending dose portion, confirming favourable safety and tolerability in healthy volunteers. IMP761 is described as a first-in-class LAG-3 agonist antibody and remains the only LAG-3 agonist currently in clinical development.

What the Phase I data actually showed

Primary endpoint met with clean safety profile

The study is a randomised, placebo-controlled, double-blind first-in-human trial (NCT06637865) conducted by the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands. IMP761 was reported as safe and very well tolerated across all dose levels tested, ranging from 0.9 mg/kg to 7 mg/kg.

Pharmacokinetic data from single ascending doses indicates that IMP761 may support once per 4-week dosing, a clinically convenient dosing interval that could ease administration in future indication development programmes.

Statistically significant pharmacodynamic activity

To assess IMP761’s pharmacological activity early in development, the study employed CHDR’s keyhole limpet haemocyanin (KLH) challenge model. KLH is a validated human immune response model that uses a foreign protein to trigger a controlled, measurable immune reaction in healthy volunteers, allowing researchers to evaluate how a drug modulates immune activity before progressing to patient populations.

The key efficacy signals observed across cohorts were:

  • Reduction of local inflammatory responses versus placebo
  • Attenuated T-cell activity across dose cohorts
  • At 7 mg/kg, a statistically significant improvement in skin blood perfusion versus placebo (p = 0.029)

The placebo-controlled, double-blinded design strengthens the credibility of these findings, reducing the potential for bias in interpreting the pharmacodynamic results.

Dr. Frédéric Triebel, Chief Scientific Officer, Immutep

“I am very excited about this first clinical evaluation of IMP761. IMP761 is designed to selectively target overactive T cells linked to chronic inflammation and is now showing clear immunosuppressive effects at dose levels above 0.9 mg/kg in this placebo controlled Phase I study.”

Understanding LAG-3 agonism — why this mechanism matters for autoimmune disease

LAG-3 (Lymphocyte Activation Gene-3) is a receptor found on the surface of T cells, the white blood cells that direct the body’s immune response. In healthy individuals, LAG-3 helps regulate immune activity. In autoimmune disease, T cells become overactive and mistakenly attack the body’s own tissues.

There are two fundamentally different ways to target LAG-3, and the distinction matters considerably for investors evaluating Immutep’s pipeline:

Feature LAG-3 Antagonist LAG-3 Agonist (IMP761) Disease Target
Immune action Releases the brakes on the immune system Applies the brakes on overactive immune cells Autoimmune diseases
Effect on T cells Activates / disinhibits T cells Suppresses overactive T cells T-cell driven inflammation
Clinical use case Oncology (boost immune attack on tumours) Autoimmunity (dampen pathological immune response) Rheumatoid arthritis, others
Immutep asset Eftilagimod alpha (cancer pipeline) IMP761 Autoimmune pipeline

IMP761’s design targets activated T cells specifically at sites of inflammation, aiming to reduce pathological immune responses while preserving broader systemic immune function. This selectivity differentiates it from conventional immunosuppressants, which typically dampen the entire immune system and carry broader side effect profiles.

Preclinical data supporting IMP761’s mechanism have been published in the Journal of Immunology, with additional supporting data in oligoarticular juvenile idiopathic arthritis published in Pediatric Research, providing independent scientific validation of the approach. As the only LAG-3 agonist currently in clinical development, IMP761 holds a potential first-mover position in what could become a distinct therapeutic class.

What comes next — and why investors should watch H2 CY2026

The company has confirmed that additional trial updates are expected in H2 CY2026, representing a near-term catalyst for investors monitoring the programme’s progress. The data presented at EULAR support further evaluation of IMP761 in a Phase II setting, with the CSO specifically citing rheumatoid arthritis and other T-cell driven conditions as potential target indications.

CEO Marc Voigt also pointed to broader commercial optionality in his commentary on the results:

Marc Voigt, Chief Executive Officer, Immutep

“These first-in-human results are a pivotal milestone for Immutep and for the broader field of LAG-3 biology in autoimmunity… the program supports further clinical evaluation and potential strategic collaboration.”

The reference to “potential strategic collaboration” signals that business development discussions around IMP761 may be a component of the company’s near-term planning.

Key items for investors to monitor include:

  1. Phase II design and indication selection announcements
  2. Additional Phase I cohort data from the multiple ascending dose portion of the study
  3. Any partnership or licensing discussions tied to IMP761
  4. Further congress presentations — the EULAR poster is available on Immutep’s website

Immutep’s broader platform spans both oncology and autoimmune disease, with its LAG-3 expertise deployed across two distinct therapeutic strategies. The IMP761 results add clinical weight to the autoimmune arm of that dual pipeline, at a stage where verifiable human data carry considerably more weight than preclinical evidence alone.

Don’t Miss the Next ASX Healthcare Breakthrough

Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market on biotech and healthcare developments. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.


Frequently Asked Questions

What is a LAG-3 agonist antibody and how does IMP761 differ from LAG-3 antagonists?

A LAG-3 agonist antibody activates the LAG-3 receptor on T cells to suppress overactive immune responses, making it suitable for autoimmune diseases, whereas LAG-3 antagonists block this receptor to unleash the immune system against tumours in oncology. IMP761 is the only LAG-3 agonist currently in clinical development, distinguishing it from cancer-focused LAG-3 antagonists.

What were the key findings from Immutep's IMP761 Phase I results presented at EULAR 2026?

The Phase I study met its primary endpoint, confirming IMP761 was safe and well tolerated across doses from 0.9 mg/kg to 7 mg/kg, with statistically significant improvement in skin blood perfusion versus placebo at 7 mg/kg (p = 0.029) and attenuated T-cell activity observed across dose cohorts. Pharmacokinetic data also suggested IMP761 may support a convenient once-every-4-week dosing schedule.

What is the KLH challenge model used in the IMP761 Phase I study?

The keyhole limpet haemocyanin (KLH) challenge model is a validated human immune response model that uses a foreign protein to trigger a controlled, measurable immune reaction in healthy volunteers, allowing researchers to assess how a drug modulates immune activity before testing it in patient populations.

What are the next clinical milestones for Immutep's IMP761 programme?

Immutep has confirmed additional trial updates are expected in H2 CY2026, including data from the multiple ascending dose portion of the Phase I study, with the results supporting further evaluation in a Phase II setting targeting conditions such as rheumatoid arthritis and other T-cell driven autoimmune diseases.

Could Immutep pursue a partnership or licensing deal for IMP761?

CEO Marc Voigt commented that the IMP761 programme "supports further clinical evaluation and potential strategic collaboration," indicating that business development discussions around the asset may be part of the company's near-term planning following the positive EULAR 2026 data presentation.

Josua Ferreira
By Josua Ferreira
Partnership Director
Josua Ferreira holds a Bachelor of Commerce in Marketing and Advertising and brings a background in publication, business development, and ASX market storytelling. He has worked with listed companies across the resource sector and broader market, combining sharp commercial instincts with a genuine commitment to keeping investors informed.
Learn More
Companies Mentioned in Article

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher